Share Email Print
cover

Proceedings Paper

Infrared light utilized for photodynamic therapy by activation of rare earth phosphors for visible light generation
Author(s): Joshua E. Collins; Thiru V. Lakshman; Jarod E. Finlay; Ajith Kumar; Howard Bell; Ba T. Nguyen; Valery Belov; Jun Luo; Joseph S. Friedberg
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Introduction: Photodynamic therapy (PDT) is a treatment for cancer requiring activation of a photosensitizer for light-mediated tumor cytotoxicity. PDT is limited by tissue penetration because visible light is required for photosensitizer activation. SunstonesTM are rare-earth phosphors which up-convert energy from infrared wavelengths to emit higher energy in the visible spectrum. We utilized this unique characteristic to generate light of appropriate intensity and wavelength for photosensitizer activation and subsequent tumor cell eradication. Methods: SunstonesTM with infrared absorption at 808 and 980nm and visible two-photon emission at 549.9 and 663.1nm were used. A murine NSCLC line was used to determine in vitro toxicity of SunstonesTM and dose response curves for SunstonesTM-mediated PDT. Human NSCLC cells were incubated with/without PhotofrinTM (photosensitizer). Experimental groups included: Infrared light treatment (IR), IR+PhotofrinTM, IR+SunstonesTM, and IR+SunstonesTM+PhotofrinTM. Groups were exposed to 2.5W of 808nm light and assayed for metabolic activity. Results: In vitro toxicity assays showed no significant toxicological side effects after 1 week incubation with SunstonesTM and demonstrated linear response in cytotoxicity as treatment times and infrared dose increased. IR+SunstonesTM+PhotofriTM group showed significantly decreased metabolic activity compared to control cells, cells treated with IR+SunstonesTM, and IR alone. Conclusion: SunstonesTM are nontoxic nanocrystals capable of activating photosensitizers for PDT. Future directions include conjugation of up-converters to a novel photosensitizer and managing the selective uptake of conjugate by tumor cells.

Paper Details

Date Published: 28 February 2007
PDF: 12 pages
Proc. SPIE 6427, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI, 642717 (28 February 2007); doi: 10.1117/12.700252
Show Author Affiliations
Joshua E. Collins, Univ. of Pennsylvania (United States)
Thiru V. Lakshman, Univ. of Pennsylvania (United States)
Jarod E. Finlay, Univ. of Pennsylvania (United States)
Ajith Kumar, Univ. of Pennsylvania (United States)
Howard Bell, Univ. of Pennsylvania (United States)
Ba T. Nguyen, Univ. of Pennsylvania (United States)
Valery Belov, Univ. of Pennsylvania (United States)
Jun Luo, Univ. of Pennsylvania (United States)
Joseph S. Friedberg, Univ. of Pennsylvania (United States)


Published in SPIE Proceedings Vol. 6427:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI
David Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top